189 related articles for article (PubMed ID: 24218360)
1. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.
Díaz-Montero CM; Zidan AA; Pallin MF; Anagnostopoulos V; Salem ML; Wieder E; Komanduri K; Montero AJ; Lichtenheld MG
Immunol Res; 2013 Dec; 57(1-3):23-33. PubMed ID: 24218360
[TBL] [Abstract][Full Text] [Related]
2. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
3. L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.
Watson HA; Durairaj RRP; Ohme J; Alatsatianos M; Almutairi H; Mohammed RN; Vigar M; Reed SG; Paisey SJ; Marshall C; Gallimore A; Ager A
Front Immunol; 2019; 10():1321. PubMed ID: 31249570
[TBL] [Abstract][Full Text] [Related]
4. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
Miller CH; Graham L; Bear HD
BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of central memory CD8 T cells is independent of CD62L-mediated trafficking to lymph nodes.
Wirth TC; Badovinac VP; Zhao L; Dailey MO; Harty JT
J Immunol; 2009 May; 182(10):6195-206. PubMed ID: 19414773
[TBL] [Abstract][Full Text] [Related]
8. IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model.
Yu EM; Cho E; Singh R; Kim SH; Han C; Han S; Lee DG; Kim YH; Kwon BS; Choi BK
Cells; 2021 Aug; 10(8):. PubMed ID: 34440787
[TBL] [Abstract][Full Text] [Related]
9. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
Schuster K; Gadiot J; Andreesen R; Mackensen A; Gajewski TF; Blank C
Eur J Immunol; 2009 Nov; 39(11):2981-90. PubMed ID: 19658092
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
11. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating CD62L+PD-1-CD8 T cells retain proliferative potential via Bcl6 expression and replenish effector T cells within the tumor.
Gong Y; Suzuki T; Kozono H; Kubo M; Nakano N
PLoS One; 2020; 15(8):e0237646. PubMed ID: 32845913
[TBL] [Abstract][Full Text] [Related]
13. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes.
Yang S; Liu F; Wang QJ; Rosenberg SA; Morgan RA
PLoS One; 2011; 6(7):e22560. PubMed ID: 21829468
[TBL] [Abstract][Full Text] [Related]
14. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
Wang X; Berger C; Wong CW; Forman SJ; Riddell SR; Jensen MC
Blood; 2011 Feb; 117(6):1888-98. PubMed ID: 21123821
[TBL] [Abstract][Full Text] [Related]
15. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.
Kaiser AD; Gadiot J; Guislain A; Blank CU
Cancer Immunol Immunother; 2013 Mar; 62(3):503-15. PubMed ID: 23001162
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
19. Homogenization of TCR repertoires within secondary CD62Lhigh and CD62Llow virus-specific CD8+ T cell populations.
Kedzierska K; Venturi V; Valkenburg SA; Davenport MP; Turner SJ; Doherty PC
J Immunol; 2008 Jun; 180(12):7938-47. PubMed ID: 18523257
[TBL] [Abstract][Full Text] [Related]
20. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.
Bachmann MF; Wolint P; Schwarz K; Jäger P; Oxenius A
J Immunol; 2005 Oct; 175(7):4686-96. PubMed ID: 16177116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
